ClinicalTrials.gg
CompletedNCT06560489Updated May 11, 2026

Pharmacokinetics and Efficacy of Multiple Dosing of LP-98 for Injection in HIV-infected Patients

A Phase 1/2 interventional study of Subjects will be randomly assigned to receive 1.25 mg, 2.5 mg, 5 mg, or 10 mg of LP-98. in Hiv, sponsored by Shanxi Kangbao Biological Product Co., Ltd.. Completed at 1 site in China. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-05-11.

Primary conditionAcquired Immunodeficiency Syndrome(the registry's first term)UnverifiedIs this wrong?The registry often attaches Acquired Immunodeficiency Syndrome to studies about something else, and this study's title and listed conditions do not name it. No better condition is named, so the registry's term is kept.

Sponsored by Shanxi Kangbao Biological Product Co., Ltd. · Phase 1/2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
40
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Study summary

A Randomized, Double-Blind, Parallel-Group, Exploratory Clinical Study to Evaluate the Safety, Pharmacodynamic Effects, and Pharmacokinetic Characteristics of Multiple Subcutaneous Injections of LP-98 in Treatment-Naive HIV-Infected Individuals

Read the detailed description

This is a randomized, double-blind, parallelize-designed, multicenter, exploratory clinical study to evaluate the safety, PD, and PK profile of multiple subcutaneous injections of LP-98 in HIV-infected individuals who have not received antiviral therapy.

This study consisted of 4 cohorts with 10 subjects in each group, who were randomly assigned to receive LP-98 treatment of 1.25 mg, 2.5 mg, 5 mg, and 10 mg. The method of administration was subcutaneous injection, and the interval of administration was 14 days, a total of 4 doses.

The study included screening period (D-28\~D-1), treatment period (D1-D57), and follow-up period (D58\~D71).

02

Conditions studied

  • Hiv

Browse trials for

Keywords

  • LP-98
  • Double-Blind
  • Treatment-Naive HIV-Infected Individuals
03

In context

Acquired Immunodeficiency Syndrome Unverified

3,038 studies on the registry are indexed under Acquired Immunodeficiency Syndrome; 308 are open to participants now.

This study's enrollment of 40 is below the median of 96 across 2,253 interventional studies indexed under Acquired Immunodeficiency Syndrome.

Browse Acquired Immunodeficiency Syndrome studies →

Lead sponsor

Shanxi Kangbao Biological Product Co., Ltd. is the lead sponsor of 6 studies on the registry; 1 is open to participants now.

Compared within Acquired Immunodeficiency Syndrome, the registry's first condition term, which may not be this study's main condition. Counted across the registry records on this site, refreshed daily. How we classify →

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Voluntarily participate in the study and obtain prior to any study-related evaluation;
  2. Aged 18-65 years at the time of the screening visit (including the cut-off), male or female;
  3. At the time of screening visit, the weight of male subjects is not less than 50 kg and that of female subjects is not less than 45 kg;
  4. Plasma RNA level ≥1000 copies /mL, CD4+T lymphocyte count ≥200 /μL;
  5. For female subjects: Only subjects with no were included, including surgical sterilization at least 6 weeks prior to the screening visit (documented hysterectomy or bilateral oopectomies), and menopause ≥12 months prior to the screening visit (menopause confirmed by follicle stimulating hormone (FSH) level ≥40IU/L);
  6. For male subjects with fertile female partners, consent must be given to the use of non-drug for 14 days prior to dosing, during the study period, and for 3 months after dosing. Male subjects are not allowed to donate sperm during this period;
  7. Be willing to comply with visits, study treatments, laboratory tests, and other study-related procedures and requirements as specified in the study protocol.

Exclusion criteria

Exclusion Criteria:

  1. is allergic to the drug product or its , or has a history of severe allergy (including any food allergy or drug allergy);
  2. have received antiviral therapy (ART), or been vaccinated against ;
  3. Have a history of serious illness or other serious chronic diseases;
  4. Have a history of mental illness, or have a family history of mental illness;
  5. any of the following conditions exist: i. Unexplained persistent irregular fever above 38 °C within 1 month before or during the screening period; ii. Persistent diarrhea (more than 3 stools/day) within 1 month before or during the screening period; iii. Severe infection, opportunistic infection, or sepsis in the 6 months prior to or during the screening period;
  6. surface antigen (HBsAg) positive, or antibody (HCV-Ab) positive;
  7. The 12-lead was abnormal and during screening, such as interval (Fridericia correction) > 450 ms in male and > 470 ms in female;
  8. (ALT), aspartate aminotransferase (AST) > 1.5 times , or total > 1.5 times ULN during screening;
  9. Serum (Ccr) at screening was \< 60 mL/min (calculated according to Cockcroft-Gault formula);
  10. A known or suspected history of drug abuse (morphine, methamphetamine, ketamine, dimethylene dioxyamphetamine, THC, cocaine), or a positive baseline drug screening test;
  11. Heavy drinking in the year before screening (drinking more than 14 standard units per week, 1 standard unit containing 14 g of alcohol, such as 5% beer 360 ml, 40% spirits 45 ml, 12% wine 120 ml); Or fail to comply with the no-alcohol policy for the duration of the study;
  12. Smoking more than 5 cigarettes per day in the 3 months prior to screening, or failing to comply with the no-smoking policy during the study period;
  13. have received any vaccine in the three months prior to screening, or plan to receive any vaccine during the study period;
  14. received any investigational drug therapy or participated in any drug/investigational device trial within 3 months prior to dosing;
  15. had undergone a major surgical procedure within 30 days prior to dosing or planned to undergo a major surgical procedure during the study period;
  16. Those who have donated blood or lost blood ≥ 400 ml or received blood transfusion within 3 months before screening;
  17. There are other circumstances that are not suitable for participation in this study.
Terms in these criteria, in plain language(15)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Reproductive potential

Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.

Criteria about it usually ask for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
40 participants (actual)

Study arms

  • Experimental
    Dose level(1.25mg)

    This study consisted of 4 cohorts with 10 subjects in each group, who were randomly assigned to receive LP-98 treatment of 1.25 mg, 2.5 mg, 5 mg, and 10 mg. The method of administration was subcutaneous injection, and the interval of administration was 14 days, a total of 4 doses.

    Drug: Subjects will be randomly assigned to receive 1.25 mg, 2.5 mg, 5 mg, or 10 mg of LP-98.

  • Experimental
    Dose level(2.5mg)

    This study consisted of 4 cohorts with 10 subjects in each group, who were randomly assigned to receive LP-98 treatment of 1.25 mg, 2.5 mg, 5 mg, and 10 mg. The method of administration was subcutaneous injection, and the interval of administration was 14 days, a total of 4 doses.

    Drug: Subjects will be randomly assigned to receive 1.25 mg, 2.5 mg, 5 mg, or 10 mg of LP-98.

  • Experimental
    Dose level(5mg)

    This study consisted of 4 cohorts with 10 subjects in each group, who were randomly assigned to receive LP-98 treatment of 1.25 mg, 2.5 mg, 5 mg, and 10 mg. The method of administration was subcutaneous injection, and the interval of administration was 14 days, a total of 4 doses.

    Drug: Subjects will be randomly assigned to receive 1.25 mg, 2.5 mg, 5 mg, or 10 mg of LP-98.

  • Experimental
    Dose level(10mg)

    This study consisted of 4 cohorts with 10 subjects in each group, who were randomly assigned to receive LP-98 treatment of 1.25 mg, 2.5 mg, 5 mg, and 10 mg. The method of administration was subcutaneous injection, and the interval of administration was 14 days, a total of 4 doses.

    Drug: Subjects will be randomly assigned to receive 1.25 mg, 2.5 mg, 5 mg, or 10 mg of LP-98.

Interventions

  • DrugSubjects will be randomly assigned to receive 1.25 mg, 2.5 mg, 5 mg, or 10 mg of LP-98.

    This study consisted of 4 cohorts with 10 subjects in each group, who were randomly assigned to receive LP-98 treatment of 1.25 mg, 2.5 mg, 5 mg, and 10 mg. The method of administration was subcutaneous injection, and the interval of administration was 14 days, a total of 4 doses.

06

What researchers measure

Primary outcomes

  1. Changes from baseline in respiration rate of Vital Signs.

    Respiration rate in times / minute

    Time frame: Within 71 days after the first administration.

  2. Changes from baseline in blood pressure of Vital Signs.

    Blood pressure in mmHg

    Time frame: Within 71 days after the first administration.

  3. Changes from baseline in Blood lactate of Laboratory Examination.

    Changes of blood lactate will be recorded.

    Time frame: Within 71 days after the first administration.

  4. Changes from baseline in body temperature of Vital Signs.

    Body temperature in Celsius degree

    Time frame: Within 71 days after the first administration.

  5. Changes from baseline in red blood cell count of Laboratory Examination.

    Red blood cell count in whole blood is reported in the form of number.

    Time frame: Within 71 days after the first administration.

  6. Changes from baseline in white blood cell count of Laboratory Examination.

    White blood cell count in whole blood is reported in the form of number.

    Time frame: Within 71 days after the first administration.

  7. Changes from baseline in neutrophil count of Laboratory Examination.

    Neutrophil count in whole blood is reported in the form of number.

    Time frame: Within 71 days after the first administration.

  8. Changes from baseline in lymphocyte count of Laboratory Examination.

    Lymphocyte count in whole blood is reported in the form of number.

    Time frame: Within 71 days after the first administration.

  9. Changes from baseline in platelet count of Laboratory Examination.

    Platelet count in whole blood is reported in the form of number.

    Time frame: Within 71 days after the first administration.

  10. Changes from baseline in hemoglobin of Laboratory Examination.

    Changes of hemoglobin concentration(g/dL)in whole blood will be recorded.

    Time frame: Within 71 days after the first administration.

  11. Changes from baseline in PT of Laboratory Examination.

    Prothrombin time (PT) is a screening test for exogenous coagulation factors.

    Time frame: Within 71 days after the first administration.

  12. Changes from baseline in INR of Laboratory Examination.

    International standardized ratio (INR) is calculated from prothrombin time and international sensitivity index (ISI) of the reagent.

    Time frame: Within 71 days after the first administration.

  13. Changes from baseline in APTT of Laboratory Examination.

    Activated partial thromboplastin time (APTT) is a screening test for endogenous coagulation factors.

    Time frame: Within 71 days after the first administration.

  14. Changes from baseline in total bilirubin of Laboratory Examination.

    Changes of total bilirubin concentration (μmol/L) in serum will be recorded.

    Time frame: Within 71 days after the first administration.

  15. Changes from baseline in direct bilirubin of Laboratory Examination.

    Changes of direct bilirubin concentration (μmol/L) in serum will be recorded.

    Time frame: Within 71 days after the first administration.

  16. Changes from baseline in ALT of Laboratory Examination.

    Changes of ALT concentration (U/L) in serum will be recorded.

    Time frame: Within 71 days after the first administration.

  17. Changes from baseline in AST of Laboratory Examination.

    Changes of AST concentration (U/L) in serum will be recorded.

    Time frame: Within 71 days after the first administration.

  18. Changes from baseline in total protein of Laboratory Examination.

    Changes of total protein concentration (g/L) in serum will be recorded.

    Time frame: Within 71 days after the first administration.

  19. Changes from baseline in albumin of Laboratory Examination.

    Changes of albumin concentration (g/L) in serum will be recorded.

    Time frame: Within 71 days after the first administration.

  20. Changes from baseline in urea of Laboratory Examination.

    Changes of urea concentration (mmol/L) in serum will be recorded.

    Time frame: Within 71 days after the first administration.

  21. Changes from baseline in creatinine of Laboratory Examination.

    Changes of creatinine concentration (μmol/L) in serum will be recorded.

    Time frame: Within 71 days after the first administration.

  22. Changes from baseline in uric acid of Laboratory Examination.

    Changes of uric acid concentration (μmol/L) in serum will be recorded.

    Time frame: Within 71 days after the first administration.

  23. Changes from baseline in glucose of Laboratory Examination

    Changes of glucose concentration (mmol/L) in serum will be recorded.

    Time frame: Within 71 days after the first administration.

  24. Changes from baseline in potassium of Laboratory Examination.

    Changes of potassium concentration (mmol/L) in serum will be recorded.

    Time frame: Within 71 days after the first administration.

  25. Changes from baseline in sodium of Laboratory Examination.

    Changes of sodium concentration (mmol/L) in serum will be recorded.

    Time frame: Within 71 days after the first administration.

  26. Changes from baseline in chlorine of Laboratory Examination.

    Changes of chlorine concentration (mmol/L) in serum will be recorded.

    Time frame: Within 71 days after the first administration.

  27. Changes from baseline in urine specific gravity of Laboratory Examination.

    Changes of urine specific gravity will be recorded.

    Time frame: Within 71 days after the first administration.

  28. Changes from baseline in urine pH of Laboratory Examination.

    Changes of urine pH value will be recorded.

    Time frame: Within 71 days after the first administration.

  29. Changes from baseline in urine glucose of Laboratory Examination.

    Changes of urine glucose will be examined by qualitative test (positive or negative).

    Time frame: Within 71 days after the first administration.

  30. Changes from baseline in urine protein of Laboratory Examination.

    Changes of urine protein will be examined by qualitative test (positive or negative).

    Time frame: Within 71 days after the first administration.

  31. Changes from baseline in urine ketone body of Laboratory Examination.

    Changes of urine ketone body will be examined by qualitative test (positive or negative).

    Time frame: Within 71 days after the first administration.

  32. Changes from baseline in urine white blood cell of Laboratory Examination.

    Changes of white blood cell in urine will be examined by qualitative test (positive or negative).

    Time frame: Within 71 days after the first administration.

  33. Changes from baseline in urine bilirubin of Laboratory Examination.

    Changes of urine bilirubin will be examined by qualitative test (positive or negative).

    Time frame: Within 71 days after the first administration.

  34. Changes from baseline in urine occult blood of Laboratory Examination.

    Changes of urine occult blood will be examined by qualitative test (positive or negative).

    Time frame: Within 71 days after the first administration.

  35. Changes from baseline in Electrocardiogram.

    The cardiac rhythm is showed in electrocardiogram in the form of continuous curve. Changes of this continuous curve will be recorded,To evaluate the incidence of abnormal electrocardiogram.

    Time frame: Within 71 days after the first administration.

  36. Changes from baseline in CK of Laboratory Examination

    Changes of CK concentration (U/L) in serum will be recorded.

    Time frame: Within 71 days after the first administration.

  37. Changes from baseline in CK-MB of Laboratory Examination

    Changes of CK-MB concentration (ng/mL) in serum will be recorded.

    Time frame: Within 71 days after the first administration.

  38. Changes from baseline in LDH of Laboratory Examination

    Changes of LDH concentration (U/L) in serum will be recorded.

    Time frame: Within 71 days after the first administration.

  39. Changes from baseline in ALP of Laboratory Examination

    Changes of ALP concentration (U/L) in serum will be recorded.

    Time frame: Within 71 days after the first administration.

  40. Changes from baseline in Triglyceride of Laboratory Examination

    Changes of Triglyceride concentration (mmol/L) in serum will be recorded.

    Time frame: Within 71 days after the first administration.

  41. Changes from baseline in CHOL of Laboratory Examination

    Changes of CHOL concentration (mmol/L) in serum will be recorded.

    Time frame: Within 71 days after the first administration.

  42. Changes from baseline in TP of Laboratory Examination

    Changes of TP concentration (g/L) in serum will be recorded.

    Time frame: Within 71 days after the first administration.

  43. Changes from baseline in ALB of Laboratory Examination

    Changes of ALB concentration (g/L) in serum will be recorded.

    Time frame: Within 71 days after the first administration.

  44. Changes from baseline in UA of Laboratory Examination

    Changes of UA concentration (μmol/L) in serum will be recorded.

    Time frame: Within 71 days after the first administration.

Secondary outcomes

  1. Changes from baseline in Immunogenic blood collection of Laboratory Examination.

    Changes of immunogenic blood collection will be recorded.The historical changes of test results (including positive rate and titer) of various indicators were counted.

    Time frame: Within 71 days after the first administration.

  2. Changes from baseline in HIV viral load detection of Laboratory Examination.

    Changes of HIV viral load detection will be recorded.

    Time frame: Within 71 days after the first administration.

  3. Changes from baseline in CD4+T cell counts of Laboratory Examination.

    Changes of CD4+T cell counts will be recorded.

    Time frame: Within 71 days after the first administration.

07

Study locations

1 site
  • Henan Provincial Hospital for Infectious Diseases (Zhengzhou Sixth People's Hospital)
    Zhengzhou, Henan, China
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Sep 2024 to primary completion in Jan 2025, 4 months.

Of 29 phase 1/2 interventional studies under Acquired Immunodeficiency Syndrome, half reached primary completion within 42 months of starting (the median), counting those still running; a quarter within 24. This study's 4 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 15, 2024
First posted
Aug 19, 2024
StartActual
Sep 2, 2024
Primary completionActual
Jan 10, 2025
CompletionActual
Aug 22, 2025
Last update
May 11, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 11, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06560489
Lead sponsor
Shanxi Kangbao Biological Product Co., Ltd.
Collaborators
Institute of Pathogen Biology, Beijing, China
Responsible party
Sponsor
First posted
Aug 19, 2024
Start date
Sep 2, 2024
Primary completion
Jan 10, 2025
Completion
Aug 22, 2025
Last update
May 11, 2026

Study contacts

Qingxia Zhao, Doctor
study director · Henan Provincial Hospital for Infectious Diseases (Zhengzhou Sixth People's Hospital)

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion